Advertisement

Picture Enterprise Lithuania Life Sciences Baltics 2021 Digital 650x95px
Organisation › Details

Vectura (Group)

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.2 Vectura has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline, UCB and Tianjin KingYork Group Company Limited. Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. *

 

Period Start 1999-01-01 established
  Today Vectura Group plc (LSE: VEC)
  Predecessor Vectura Ltd.
Products Industry respiratory drug delivery technology
  Industry 2 drug development services
     
  Street 1 Prospect West
  City SN14 6FH Chippenham, Wiltshire
  Tel +44-1249-667700
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency GBP
  Annual sales 191,000,000 (revenue, net, consolidated (2020) 2000-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2021-07-13

Advertisement

Picture Enterprise Lithuania Life Sciences Baltics 2021 Digital 650x95px

More documents for Vectura (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px




» top